Heterogeneity of enrolment criteria for ongoing smouldering myeloma trials

Br J Haematol. 2022 Jun;197(6):e86-e88. doi: 10.1111/bjh.18102. Epub 2022 Feb 28.

Authors

Mohammad Ahsen Soomro¹, James Hoffman², Aaron Michael Goodman³, Douglas Weston Sborov⁴, Ghulam Rehman Mohyuddin⁴

Affiliations

¹ Medical College, Aga Khan University, Karachi, Pakistan.
² Division of Hematology, Sylvester Comprehensive Cancer Center, University of Miami, Coral Gables, Florida, USA.
³ Division of Blood and Marrow Transplantation, University of California San Diego, San Diego, California, USA.
⁴ Division of Hematology and Hematological Malignancies, University of Utah, Salt Lake City, Utah, USA.

PMID: 35229286
DOI: 10.1111/bjh.18102

No abstract available

Publication types

Letter

MeSH terms

Humans
Longitudinal Studies
Multiple Myeloma* / diagnosis
Multiple Myeloma* / therapy
Smoldering Multiple Myeloma*